<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877120</url>
  </required_header>
  <id_info>
    <org_study_id>CEI-011-1-17</org_study_id>
    <nct_id>NCT03877120</nct_id>
  </id_info>
  <brief_title>Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán</brief_title>
  <official_title>Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Medico Nacional La Raza, IMSS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de La Frontera</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Medico Nacional La Raza, IMSS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cessation of alcohol consumption of people suffering from alcohol abuse frequently leads&#xD;
      to the development of an alcohol withdrawal syndrome (AWS).&#xD;
&#xD;
      The ethylic suppression syndrome is defined as the appearance of two or more data of&#xD;
      autonomic hyperactivity, nausea, hallucinations and seizures associated with the cessation of&#xD;
      alcohol consumption. For its evaluation, the CIWA-Ar scale is used, which guides the&#xD;
      treatment based on benzodiazepines but with many adverse effects, so sedatives have been&#xD;
      tried, among them dexmedetomidine, an alpha-agonist with action in the locus caeruleus, with&#xD;
      variable results. Objectives: The investigators aimed to compare the DEX vs. Diazepam, for&#xD;
      moderate disease, applying the CIWA-Ar scale, in participants with severe to moderate AWS.&#xD;
      Methodology: 40 participants with CIWA-Ar greater than 10 points, the investigators are&#xD;
      collected and randomized into two groups: one under treatment with diazepam (Group Diazepam)&#xD;
      and another with dexmedetomidine (Group Dexmedetomidine), until the CIWA-Ar was reduced to&#xD;
      less than 10, and adverse effects the investigators also reported. The analysis was done with&#xD;
      student t. Results: The average duration of treatment with diazepam was 5.5 days (IC 95 =&#xD;
      6.6-3.8), the average duration of treatment with dexmedetomidine was 3.1 days (95% CI =&#xD;
      4.5-1.7), with a significant difference ( p = 0.0016). In the group with diazepam 60%&#xD;
      presented adverse effects and in the group with dexmedetomidine 25% presented them, with a&#xD;
      significant difference (p = 0.04). Conclusion: dexmedetomidine was superior to diazepam for&#xD;
      the treatment of moderate-severe alcohol withdrawal with fewer adverse effects.&#xD;
&#xD;
      KEY WORDS: Alcohol dependence · Alcohol withdrawal syndrome · Dexmedetomidine · Diazepam ·&#xD;
      Benzodiazepines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol withdrawal syndrome AWS (Alcohol Withdrawal Syndrome), is defined as the appearance&#xD;
      of two or more data of autonomic hyperactivity, nausea, hallucinations and seizures&#xD;
      associated with cessation of alcohol consumption. For its evaluation, the CIWA-Ar (Clinical&#xD;
      Institute Withdrawal Assessment for Alcohol) scale is used, which guides the treatment based&#xD;
      on benzodiazepines but a disadvantage is the related adverse effects, for which other&#xD;
      pharmacological strategies of sedation have been tried, among them Dexmedetomidine (DEX).&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      The investigators aimed to compare the DEX vs. Diazepam, for moderate disease, applying the&#xD;
      CIWA-Ar scale, in participants with severe to moderate AWS (Alcohol Withdrawal Syndrome).&#xD;
&#xD;
      MATERIALS:&#xD;
&#xD;
      Prior authorization from the ethics committee of O'Horán Hospital, Yucatán, Mexico. No.&#xD;
      Registration CEI-011-1-17, and signature of informed consent. A randomized clinical trial was&#xD;
      carried out in the Adult Emergencies service during the period July 2017-July 2018. Forty&#xD;
      participants with CIWA-Ar greater than 10 points participated. The administration of:&#xD;
&#xD;
      A) Diazepam 5-20 mg IV. B) DEX 0.2-0.7 mcg / Kg / min., until the CIWA-Ar scale decreases to&#xD;
      &lt;10.&#xD;
&#xD;
      The investigators are excluded minor patients, mild CIWA-Ar category, previous medication,&#xD;
      participants with severe cranial encephalic trauma (TBI) or mechanical ventilation&#xD;
      requirement, with chronic liver failure category C in the Child-Turcotte-Pugh classification.&#xD;
&#xD;
      RESULTS&#xD;
&#xD;
      The CIWA Ar scale average for admission was 23 points, the lowest of 10 points and the&#xD;
      highest of 38 points. The average number of days consuming alcohol prior to hospital&#xD;
      admission was 131.9, with the highest average in the group that used dexmedetomidine; the&#xD;
      average number of days after having suspended the intake until hospital admission was 1.7&#xD;
      days, being slightly higher in the group that used diazepam; the shortest time was 6 hours&#xD;
      and the longest of a week without being related to the CIWA Ar score.&#xD;
&#xD;
      The average duration of treatment with diazepam was 5.5 days (IC 95 = 6.6-3.8), The average&#xD;
      duration of treatment with dexmedetomidine was 3.1 days (95% CI = 4.5-1.7) After applying t&#xD;
      student a significant difference was found in the number of days in favor of dexmedetomidine&#xD;
      (p = 0.0016)&#xD;
&#xD;
      CONCLUSIONS&#xD;
&#xD;
      The investigators found that DEX at conventional doses, for the treatment of moderate-severe&#xD;
      alcohol withdrawal in terms of reducing the CIWA-Ar scale, in fewer days and with fewer&#xD;
      adverse effects and complications.&#xD;
&#xD;
      REFERENCES:&#xD;
&#xD;
        1. Anderson P, Lars M, Gauden G. Alchol in the Europen Union. Consume, harm and policy&#xD;
           approaches. Edit. WHO. 2012&#xD;
&#xD;
        2. Nota descriptiva N° 349: Alcohol. Organización Mundial de la Salud. 2015.&#xD;
&#xD;
        3. Encuesta Nacional de Adicciones 2011: Reporte de Alcohol. Medina-Mora ME,&#xD;
           Villatoro-Velázquez JA, Fleiz-Bautista C, et. Al. México: INPRFM; 2012.&#xD;
&#xD;
        4. Longo D, Fauci A, Kasper E, et al. Harrison: Principios de Medicina Interna. 18ª ed.&#xD;
           McGraw-Hill. México. 2012.&#xD;
&#xD;
        5. Diagnostic and statistical manual of mental disorders. 5th edition. Washington, DC:&#xD;
           American Psychiatric Association; 2013. 947 pp.&#xD;
&#xD;
        6. Carson L, Kumar N, Wong-Mckinstry. Alcohol Withdrawal Syndrome. Critical Care. 2012.&#xD;
&#xD;
        7. Jawa R, Stothert J, Shostrom V, et al. Alcohol Withdrawal Syndrome in admitted trauma&#xD;
           patients. The American Journal of Surgery (2014)208: 781-787&#xD;
&#xD;
        8. Sullivan J, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the&#xD;
           revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J&#xD;
           Addict. 1989. 84(11):1353-7.&#xD;
&#xD;
        9. Waye C, Wong M, Lee S. Implementation of a CIWA Ar Alcohol Withdrawal protocol in a&#xD;
           Veterans Hospital. South Med Jour. 2015. 108(1):23-8.&#xD;
&#xD;
       10. Ramírez D, Sánchez G. Capacidad diagnóstica de las escalas de Cushman y AWS para&#xD;
           supresión etílica. Med Int de Mex. 2013. 29(1): 26-31&#xD;
&#xD;
       11. Miller W, McCurdy L. A double-blind comparison of the efficacy and safety of lorazepam&#xD;
           and diazepam in the treatment of the acute alcohol withdrawal syndrome. Clin Ther 1984.&#xD;
           6(3):364-71.&#xD;
&#xD;
       12. Henrey G, Dery R, Bandes R. A prospective randomized trial of phenobarbital vs&#xD;
           benzodiazepines for acute alcohol withdrawal. Am Jour Eme Med. 2011. 382-85.&#xD;
&#xD;
       13. Hughes D, VanWert E, LePori L. Propofol for benzodiazepine-refractory alcohol withdrawal&#xD;
           in a non-mechanically ventilated patient. Am Jour Eme Med. 2014. 112.e3-e4.&#xD;
&#xD;
       14. Wong A, et al. Multicenter evaluation of pharmacologic management and outcomes&#xD;
           associated with severe resistant alcohol withdrawal. J Crit Care. 2014.&#xD;
&#xD;
       15. Samuels E, Szabadi E. Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its&#xD;
           Roles in the Regulation of Arousal and Autonomic Function Part I: Principles of&#xD;
           Functional Organisation. Curr Neuropharmacol. 2008; 6(3): 235-53.&#xD;
&#xD;
       16. Rovasalo A, Tohmo H, Aantaa R, Kettunen E, Palojoki R: Dexmedetomidine as an adjuvant in&#xD;
           the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatr 2006,&#xD;
           28:362-363.&#xD;
&#xD;
       17. Rayner et al. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal. Annasl&#xD;
           of intensive care. 2012. 2:12&#xD;
&#xD;
       18. VanderWeid L, Foster C, McLaren R. Evaluation of early dexmedetomidine addition to the&#xD;
           standard of care for severe alcohol withdrawal in the ICU: A retrospective controlled&#xD;
           cohort study. Jour Int Care Med. 2014. 1-7.&#xD;
&#xD;
       19. Frazee E, Personett H, Leung J, et al. Influence of dexmedetomidine therapy on the&#xD;
           management of severe alcohol withdrawal síndrome in critically ill patients. Jour Crit&#xD;
           Care. 2014. 198-302.&#xD;
&#xD;
       20. Crispo A, Daley M, Pepin J. Comparison of clinical outcomes in nonintubated patients&#xD;
           with severe alcohol withdrawal síndrome treated with continuous-infusion sedatives:&#xD;
           dexmedetomidine versus benzodiazepines. Pharm. 2014. 910-17.&#xD;
&#xD;
       21. Pita S. Determinación del tamaño muestreal. Cad Aten Prim. 1996. 138-44.&#xD;
&#xD;
       22. Farmacología Básica y clínica. P Lorenzo, A Moreno, Lizasoain, et al. 18ª ed. Editorial&#xD;
           Panamericana. España. 2010.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical Trials To compare Diazepam 5-20 mg IV or Dexmedetomidine 0.2-0.7 mcg / Kg / min., In monotherapy until the CIWA-Ar decreases to &lt;10.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Alcohol Withdrawal Scoring</measure>
    <time_frame>dosing, total dose per 24 hours period for each patient, limited to 10 days</time_frame>
    <description>Total Score = 0 - 9: absent or minimal withdrawal 10 - 19: mild to moderate withdrawal more than 20: severe withdrawal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Diazepam Received (mg)</measure>
    <time_frame>Limited to 10 days</time_frame>
    <description>Dosis total: Diacepam 5-20 mg IV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Dexmedetomidine Received (mg)</measure>
    <time_frame>dosing, total dose per 24 hours period for each patient, limited to 10 days</time_frame>
    <description>Infusión: DEX 0.2-0.7 mcg/Kg/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate average</measure>
    <time_frame>24 hours</time_frame>
    <description>mean values per 24 hours period for each patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure average</measure>
    <time_frame>24hours</time_frame>
    <description>mean values per 24 hours period for each patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>days of hospital stay</measure>
    <time_frame>24 hours limited to 10 days</time_frame>
    <description>Duration in days of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Alcohol Withdrawal Delirium</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.&#xD;
Dosage form: DEX 0.2-0.7 mcg/Kg/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine 0.004 MG/ML</intervention_name>
    <description>Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam Injectable Solution</intervention_name>
    <description>diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.</description>
    <arm_group_label>Diazepam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who received dexmedetomidine during their Emergency stay&#xD;
&#xD;
          -  Patients who received diazepam during their Emergency stay&#xD;
&#xD;
          -  CIE-10 codes consistent with alcohol withdrawal during hospitalization&#xD;
&#xD;
          -  CIWA-A score &gt;10 points&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  comorbid disease, including several with CNS trauma or cerebrovascular accidents, one&#xD;
             with end-stage metastatic carcinoma, and one patient with severe sepsis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nayely Garcia Mendez</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>4780000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Yost DA. Alcohol withdrawal syndrome. Am Fam Physician. 1996 Aug;54(2):657-64, 669. Erratum in: Am Fam Physician 1996 Dec;54(8):2377.</citation>
    <PMID>8701843</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Medico Nacional La Raza, IMSS</investigator_affiliation>
    <investigator_full_name>GARCIA MENDEZ NAYELY</investigator_full_name>
    <investigator_title>Post doc Medical Sciences, Visiting professor, Universidad de la Frontera.</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Diazepam</keyword>
  <keyword>Alcohol dependence</keyword>
  <keyword>Alcohol withdrawal syndrome</keyword>
  <keyword>Benzodiacepines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Alcohol Withdrawal Delirium</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

